Fisher & Paykel Healthcare Corporation on Friday increased its profit guidance for the 2027 financial year, citing sustained demand for its hospital products and clinical consumables. The Auckland-based medical device manufacturer now expects net profit after tax of NZ$525-565 million, up from its previous range of NZ$500-550 million provided in May.
Operating revenue guidance was marginally raised to NZ$2.47-2.57 billion from NZ$2.45-2.57 billion. The company forecast first-half revenue of about NZ$1.24 billion and net profit of approximately NZ$280 million for the six months ending September 30, representing 14% and 24% year-on-year growth, respectively.
Lewis Gradon, Managing Director and CEO, highlighted a strong start to the first half, particularly within the Hospital product group. The company attributed growth to continued demand for its latest hardware devices and shifts in clinical practice that have boosted consumable sales.
Shares of Fisher & Paykel rose more than 1% in Australian and New Zealand trading following the update.
